<DOC>
	<DOCNO>NCT02518191</DOCNO>
	<brief_summary>This prospective randomized control study conduct analyze effect Goserelin ovarian function woman breast cancer China .</brief_summary>
	<brief_title>Effects GnRHa Ovarian Function Against Chemotherapy-induced-gonadotoxicity</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Premenopausal woman 18 49 year age eligible enrollment Patients operable stage I IIIA breast cancer treatment adjuvant neoadjuvant cyclophosphamidecontaining chemotherapy plan . Eligible participant take estrogen , antiestrogens , selective estrogenreceptor modulators , aromatase inhibitor , hormonal contraceptive within month enrollment . Human chorionic gonadotropin negative urine test enter group . Informed consent , understand compliance requirement study . No significant chronic disease organ dysfunction . Exceptions make use hormonal contraception woman young 35 year age discontinue randomization . Use hormonal treatment 2 month purpose vitro fertilization cryopreservation embryo oocytes randomization . Patients metastatic lesion history bilateral ovariectomy , ovarian radiation exclude . Patients receive previous adjuvant endocrine therapy breast cancer suitable trial . Patients uterine and/or adnexal disease need medical surgical treatment suitable . Allergic active inactive excipients GnRHa exclusion criterion .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>GnRHa</keyword>
	<keyword>ovarian function</keyword>
	<keyword>anti-mullerian hormone</keyword>
</DOC>